Vivus (VVUS +5%) spikes as the FDA approves its amendment and modification to the Risk...
Vivus (VVUS +5%) spikes as the FDA approves its amendment and modification to the Risk Evaluation and Mitigation Strategy for Qsymia. The amendment, which was submitted last October, allows Qsymia to be dispensed through certified retail pharmacies in addition to the existing network of certified mail-order pharmacies, which reduces the prescribing burden for physicians and waiting times for patients seeking to initiate therapy.
From other sites
at CNBC.com (Dec 2, 2014)
at CNBC.com (Dec 1, 2014)
at CNBC.com (Oct 27, 2014)
at CNBC.com (Sep 18, 2014)
at CNBC.com (Sep 11, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs